IPSEN S A/S (IPSEY) Upgraded by JPMorgan Chase & Co. to “Neutral”

IPSEN S A/S (OTCMKTS:IPSEY) was upgraded by investment analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a report released on Monday, The Fly reports.

IPSEY has been the subject of several other reports. Goldman Sachs Group raised shares of IPSEN S A/S from a “sell” rating to a “neutral” rating in a report on Tuesday, February 19th. ValuEngine lowered shares of IPSEN S A/S from a “hold” rating to a “sell” rating in a report on Monday, April 29th.

IPSEN S A/S stock opened at $31.16 on Monday. The company has a market capitalization of $10.20 billion, a P/E ratio of 17.91 and a beta of 0.50. IPSEN S A/S has a 12-month low of $27.58 and a 12-month high of $44.60.

IPSEN S A/S Company Profile

Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.

Recommended Story: Discount Rate

The Fly

Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.